-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $120

Benzinga·10/19/2026 16:23:08
Piper Sandler analyst Biren Amin maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $115 to $120.